Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

January 6, 2021January 6, 2021

First Latin America Hypoparathyroidism Study Finds Poor Disease Control

News

People with hypoparathyroidism in Argentina, particularly those with kidney problems and high levels of phosphate in the blood, frequently experience inadequate disease control, a study found. The study is ... Read more

November 4, 2020November 6, 2020

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

News, syndicated

The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit ... Read more

October 19, 2020October 19, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

News, syndicated

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a ... Read more

September 30, 2020September 30, 2020

TransCon PTH Reduces Need for Other Therapy, Improves Quality of Life, New Data Show

News

Ascendis Pharma‘s TransCon PTH can safely treat hypoparathyroidism, reducing the need for other therapies and improving patients’ quality of life, an extension period of the PaTH Forward Phase 2 ... Read more

September 9, 2020September 9, 2020

TransCon PTH Safe, Effective, May Reduce Need for Other Therapies, Trial Data Shows

News

TransCon PTH, an investigational therapy being developed by Ascendis Pharma, safely normalized calcium and phosphate levels, and reduced the need for other treatments in adults with hypoparathyroidism, data from ... Read more

September 2, 2020September 2, 2020

Stem Cells Production Method Could Lead to New Therapies, Study Suggests

News

A novel approach for the production of parathyroid-like cells from stem cells — cells from which all others with specialized functions are generated — could help find new treatments ... Read more

July 8, 2020July 8, 2020

ProLynx Awarded NIH Grant to Develop Long-acting PTH Therapy

News

ProLynx has been awarded a small business innovation research grant from the National Institutes of Health (NIH) to develop its long-acting parathyroid hormone (PTH) therapy — known as PTH(1-34) — ... Read more

June 17, 2020June 17, 2020

Alizé Pharma 3 Rebrands as Amolyt Pharma, Plans AZP-3601 Trial

News

Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism treatment known as AZP-3601 later this year. “Our new name, Amolyt Pharma, ... Read more

May 6, 2020May 6, 2020

Calcific Tendonitis May Be Complication of Hypoparathyroidism

News

People with hypoparathyroidism may be at risk of having calcium crystals form in their tendons — a condition called calcific tendonitis — which can cause joint pain and inflammation, a ... Read more

April 15, 2020April 15, 2020

Supplement Need After Thyroid Cancer Surgery Linked to Poorer Life Quality

News

People needing to take vitamin D and calcium supplements due to very low levels soon after thyroid cancer surgery are likely to experience a decline in their quality of ... Read more